Celgene International Sárl Release: REVLIMID® (Lenalidomide)-Treated Patients With Deletion-5q MDS Who Achieve Transfusion-Independence Of At Least 26 Weeks And AML-Free Survival Associated With Cytogenetic Response

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from a retrospective analysis of patients with International Prognostic Scoring System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with del(5q) treated with REVLIMID® (lenalidomide) were presented at the American Society of Hematology annual meeting in New Orleans, La.

Help employers find you! Check out all the jobs and post your resume.